Biocompatible, Biodegradable, and Enzymatic-Cleavable MRI Contrast Agents for Early Detection of Bone Metastatic Breast Cancer

2012 ◽  
Author(s):  
Xuli Wang
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Early Detection ◽  
Contrast Agents ◽  
Metastatic Breast ◽  
Mri Contrast Agents ◽  
Mri Contrast

Utility of tumor markers for the early detection of metastatic breast cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 1072-1072
Author(s):  
I. Ertl ◽  
V. Heinemann ◽  
I. Bauerfeind ◽  
M. Untch ◽  
D. Laessig ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Early Detection ◽  
Tumor Markers ◽  
Metastatic Breast

scholarly journals All-In-One Approaches for Triple-Negative Breast Cancer Therapy: Metal-Phenolic Nanoplatform for MR Imaging-Guided Combinational Therapy

2021 ◽  
Author(s):  
Qi Xie ◽  
Shichao Li ◽  
Xingxing Feng ◽  
Jingyu Shi ◽  
Yang Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Contrast Agents ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Synergistic Effects ◽  
Mri Contrast Agents ◽  
Treatment Modalities ◽  
Therapeutic Effects ◽  
Mri Contrast ◽  
Combinational Therapy

Abstract Background Conventional chemotherapy has poor efficacy in triple-negative breast cancer (TNBC) which is highly heterogeneous and aggressive. Imaging-guided therapy is usually combined with diverse treatment modalities, could realize the integration of diagnosis and treatments. Therefore, the primary challenge for combinational therapy is designing proper delivery systems to accomplish multiple synergistic effects. Results Herein, a facile nanoplatform is manufactured to fulfill the all-in-one approaches for TNBC combinational therapy. Fe3+-based metal-phenolic networks (MPNs) with bovine serum albumin (BSA) modification serve as drug delivery carriers to encapsulate bleomycin (BLM), forming BFE NPs@BSA. It is found that BFE NPs@BSA could be further used as photothermal transduction agents and T1-weighted magnetic resonance imaging (MRI) contrast agents. Once internalized into tumor cells, released BLM could cause DNA damage, while Fenton reactions are initiated to produce highly toxic •OH. Upon laser irradiation, BFE NPs@BSA could convert light into heat to achieve synergistic therapeutic effects. Moreover, as T1-weighted MRI contrast agents, BFE NPs@BSA could provide diagnosis and treatment monitoring for individualized precise therapy. Conclusions This strategy provides an all-in-one theranostic nanoplatform for MRI-guided combinational therapy against TNBC.

scholarly journals Luteinizing Hormone-Releasing Hormone (LHRH) Conjugated Magnetite Nanoparticles as MRI Contrast Agents for Breast Cancer Imaging

2020 ◽  
Vol 10 (15) ◽  
pp. 5175
Author(s):  
Jingjie Hu ◽  
John Obayemi ◽  
Karen Malatesta ◽  
Edward Yurkow ◽  
Derek Adler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Luteinizing Hormone ◽  
Contrast Agents ◽  
Magnetite Nanoparticles ◽  
Mri Contrast Agents ◽  
Specific Detection ◽  
Mri Contrast ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone

Targeted magnetic resonance imaging (MRI) contrast agents offer platforms for the specific detection of many diseases, including cancer. This study explores the applicability of luteinizing hormone-releasing hormone-conjugated PEG-coated magnetite nanoparticles (LHRH-MNPs) to the enhancement of triple negative breast cancer (TNBC) detection. In vitro MRI studies were first performed, showing the consistent darkening effect of both MNPs and LHRH-MNPs in T2-weighted maps. Using a mouse model with an induced subcutaneous tumor, MNPs and LHRH-MNPs were injected into xenograft MDA-MB-231. This was done through intratumoral and intravenous injections, respectively, enabling direction comparisons of the two nanoparticles. Intratumorally injected LHRH-MNPs maintained T2 signals within the breast tumors up to two weeks, revealing long-term tumor enhancement ability, while the signal started to recover towards the contrast of the original tumor before injection in the case of MNPs at 24 h post injection. For intravenous administration, LHRH-MNPs continued to darken breast tumor 24 h following injection, whereas contrast enhancement was not obvious in animals injected with MNPs. These results show the potential of LHRH-MNPs as negative contrast agents for the specific detection of TNBC.

CA 125 in the early detection of metastatic breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e12015-e12015 ◽  
Author(s):  
I. Ertl ◽  
V. Heinemann ◽  
D. Laessig ◽  
D. Nagel ◽  
D. Seidel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Early Detection ◽  
Metastatic Disease ◽  
False Negative ◽  
Metastatic Breast ◽  
High Specificity ◽  
Ca 125 ◽  
Marker Combination

e12015 Background: Kinetics of CA 15–3 and CEA have a high specificity in the early detection (= asymptomatic patients) of metastatic breast cancer disease. However, this high specificity is associated with a lack of sensitivity (false-negative results). To decrease the number of false negative (FN) patients, the additional diagnostic potential of CA 125 kinetics was evaluated. Methods: We analysed 1,011 follow-up samples of 95 patients. Forty-seven of these patients showed metastatic recurrence during follow-up. Based on analyses, published previously, a reproducible increase of CA 125, CA 15–3, or CEA ≥100% based on the individual baseline value of each patient was selected as a reliable indicator for metastatic disease. Results: None of the 48 patients with NED had a reproducible increase of either CEA, CA 15–3, or CA125, i.e., all three tumor markers reached a specificity of 100%. At the time of first metastatic disease, the overall sensitivity was 29.8% for CA 125, 44.7% for CA 15–3, and 21.3% for CEA. In 7 patients (14.9%) only CA 125, in 14 patients (29.8%) only CA 15–3 and in 6 patients (12.8%) only CEA increased. In 8 patients (17.0%) more than one marker increased. The sensitivity of the CA 15–3/CEA combination was 59.6% (95%-CI: 45.5%-73.6%). With the additional use of CA 125, the sensitivity could be increased by 14.9% to 74.5% (95%-CI: 62.0–86.9%). The sensitivity of the marker combination was 66.6% for metastases in one site (n = 33) and 100% for metastases in more than one site (n = 14). Conclusions: This retrospective analysis indicates that CA 125 increased the sensitivity of the CA 15–3/CEA combination by 14.9% without loss of specificity. The combined use of CA15–3/CEA/CA125 may therefore be helpful for early detection of metastatic disease. The usefulness of this approach is presently verified in a prospective trial. [Table: see text]

scholarly journals Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis

2016 ◽  
Vol 37 (5) ◽  
pp. 461-470 ◽  
Author(s):  
Dharanija Madhavan ◽  
Cike Peng ◽  
Markus Wallwiener ◽  
Manuela Zucknick ◽  
Juliane Nees ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Early Detection ◽  
Prognostic Value ◽  
Metastatic Breast ◽  
Circulating Mirnas
Sign in / Sign up

Export Citation Format

Share Document